Metformin protects retinal ganglion cells in a preclinical model of retinal ischemia/reperfusion injury and stabilizes visual field in diabetic patients with glaucoma
7.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-25 07:57
摘要：
Metformin, a widely used diabetes medication, demonstrates neuroprotective effects in retinal ganglion cells, crucial for vision. In a preclinical mouse model of retinal ischemia/reperfusion injury, metformin significantly reduced retinal ganglion cell loss and preserved retinal structure. Clinically, diabetic patients with glaucoma treated with metformin maintained stable visual field parameters over six months, contrasting with deterioration in those treated with insulin. These findings suggest metformin's potential as a therapeutic agent in glaucoma management, warranting further investigation into its mechanisms and efficacy.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
1.0
关键证据
Metformin prevented retinal ganglion cell loss in a preclinical model.
Clinical study showed stable visual field parameters in patients treated with metformin.
Metformin's neuroprotective effects are attributed to its pleiotropic properties.
真实性检查
否
AI评分总结
Metformin, a widely used diabetes medication, demonstrates neuroprotective effects in retinal ganglion cells, crucial for vision. In a preclinical mouse model of retinal ischemia/reperfusion injury, metformin significantly reduced retinal ganglion cell loss and preserved retinal structure. Clinically, diabetic patients with glaucoma treated with metformin maintained stable visual field parameters over six months, contrasting with deterioration in those treated with insulin. These findings suggest metformin's potential as a therapeutic agent in glaucoma management, warranting further investigation into its mechanisms and efficacy.